In previous trials, the Soberana 02 vaccine candidate generated antibody response in about 80% of the people who were administered two doses

Amid growing accusations of vaccine hoarding by global north countries and patents blocking vaccine production, researcher and filmmaker Beth Geglia writes about the importance of supporting Cuba’s vaccines which will be available to all

Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the “first interim analysis” of phase-3 trials.

In this final and decisive phase of trials, the objective is to evaluate the efficacy, safety and immunogenicity of Soberana 02. If the vaccine produces fruitful results, Cuba will become the first country in the Latin American and the Caribbean region to develop its own vaccine

Cuba is the only country in the Latin American and the Caribbean region that is working to develop its own vaccines against COVID-19. The country has four vaccine candidates. Two of them, Soberana 02 of the Finlay Vaccine Institute (IFV) and Abdala of the Center for Genetic Engineering and Biotechnology (CIGB), will begin the third phase of clinical trials in March

Bolivia hopes to vaccinate up to 20% of its population in the first quarter of this year. The health ministry has endorsed Russia’s Sputnik V and China’s CoronaVac vaccines against COVID-19

As trials for vaccine candidates continue, the question of which countries will gain access to it has become pressing. Low-income countries are likely to suffer in this regard

The study analyzed the immune memory against the virus in 185 patients who had recovered from COVID-19. These included patients who were asymptomatic and those who exhibited severe clinical symptoms

The extension comes as the country continues to battle the COVID-19 pandemic, with Maduro securing 10 million Sputnik V vaccine doses.

If we plan to vaccinate the entire Indian people, the states need to be involved in a big way, however, the Modi government has so far centralized all aspects of the management of the epidemic, treating it only as an administrative problem.

Newsclick’s Prabir Purkayastha and immunologist Dr. Satyajit Rath discuss the challenges of taking a vaccine to the people in countries like India. They also look at the various vaccine candidates in contention

Even if the major economies can solve their own problems of procuring the vaccines by jumping the queue with money or captive production capacities, what about the rest of the world?